NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NMN was only considered as a source of cellular energy and an intermediate in NAD+ biosynthesis, currently, the attention of the scientific community has been paid on anti-aging activity and a variety of health benefits and pharmacological activities of NMN which are related to the restoring of NAD+. Thus, NMN has therapeutic effects towards a range of diseases, including age-induced type 2 diabetes, obesity, cerebral and cardiac ischemia, heart failure and cardiomyopathies, Alzheimer’s disease and other neurodegenerative disorders, corneal injury, macular degeneration and retinal degeneration, acute kidney injury and alcoholic liver disease.
NMN powder in general is typically produced via chemical or enzymatic synthesis, or fermentation biosynthesis. There are pros and cons to all three methods.
Chemical synthesis is expensive and labor intensive, and all raw ingredients used are categorized as “unnatural,” i.e., not from biological systems. There are, however, some advantages from the manufacturer’s perspective. The yield is well suited to mass NMN powder production, and all of those unnatural raw ingredients can be carefully controlled. But there are a number of drawbacks as well. Some of the solvents used in the manufacturing process are seriously bad from an environmental standpoint, and impurities and by-products can be challenging to remove from the finished product – that’s seriously bad for the consumer.
Enzymatic production of NMN powder, on the other hand, is considered a “green preparation method.” Like the chemical route, it’s pricey, but it offers a higher yield and impressively high purity. The finished NMN ticks all the boxes – stable, easily absorbed, lightweight, low density, and a low molecular structure.
Fermentation has also been explored as a method of producing NMN, but yield, though high quality, is pretty abysmal, so many supplement companies quite sensibly look to other, more efficacious processes.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability of production of NMN powder
3、Industrial leading technology: 15 domestic and international NMN patents
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
5、Multiple in vivo studies show that Bontac NMN powder is safe and effective
6、Provide one-stop product solution customization service
7、NMN raw material supplier of famous David Sinclair team of Harvard University.
Aging, as a natural process is identified by downregulation of energy production in mitochondria of various organs such as brain, adipose tissue, skin, liver, skeletal muscle and pancreas due to the depletion of NAD+ . NAD+ levels in the body decrease as a consequence of increasing NAD+ consuming enzymes when aging There are three different biosynthesis pathways to produce NAD+ in mammalian cells including de novo synthesis from tryptophan, salt and Preiss-Handler pathways. Among these three pathways, NMN is an interproduct by is involved in NAD+ biosynthesis through salt and Preiss-Handler pathways. The salvage pathway is the most efficient and the main route for the NAD+ biosynthesis, in which nicotinamide and 5-phosphoribosyl-1-pyrophosphate are converted to NMN with the enzyme of NAMPT followed by conjugation to ATP and conversion to NAD by NMNAT. Furthermore, NAD+ consuming enzymes are responsible for degradation of NAD+ and consequence nt formation of nicotinamide as a by-product.
The safety of NMN powder cannot be assessed since required clinical and toxicological studies have not been completed yet to establish the recommended safe levels for long term administration. Nevertheless, their safety and efficacy are uncertain and unreliable since most of them have not been back by Rigorous scientific preclinical and clinical testing. This issue has been arisen as manufacturers are hesitant to pay for research and clinical trials due to potential lower profit margin, and there is no authorizing agency to regulate NMN products because it is often product sold as functional food than heavily regulated therapeutic drug. Therefore, more strict approval process has been demanded by consumer advocacy groups requesting regulatory agencies to set standard and restrictions for marketing anti-aging health products, considering safety, health and wellbeing of N red besumers. a panacea for the elderly, because boosting NAD levels when not required may yield some detrimental effects. Therefore, the dose and frequency of NMN supplementation should be carefully prescribed depending on the type of age-related deficiency and all other confronting health conditions of the people. Other NAD precursors over have been studied to diverse age-related deficiencies and they are used for particular deficiencies, only after they are proven for effectiveness and safe to use. Therefore, the same principle should be applied to NMN as well
First, inspect the factory. After some screening, NMN companied that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMN powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMN powder produced by Bontac reach the purity of 99.9%. Finally, a professional test spectrum is needed to prove it. Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound ca n be preliminarily determined.
Introduction Alpers' disease is both a neurodegenerative disorder and a metabolic disorder, which is tightly linked to mitochondrial dysfunction and mutations in the catalytic subunit of polymerase gamma (POLG) gene. Noteworthily, supplementation of NAD precursor, nicotinamide riboside (NR), is evidenced to explicitly ameliorate mitochondrial defects in cortical organoids of patients with Alpers' disease. About Alpers’ disease Alpers’ disease is an autosomal recessive disorder, which is often accompanied with cortical neuronal loss as well as depletion of mitochondrial DNA (mtDNA) and complex I (CI). The disease occurs in about 1 in 100,000 newborns. Most individuals with Alpers’ disease show no symptoms at birth. Diagnosis is generally established by determining the POLG gene. Once onset (usually between first and third years of life), patients may present the symptoms such as progressive encephalopathy, epilepsy, myoclonus, and myasthenia gravis. Currently, there is no effective method to cure this disease. Establishment of Alpers' disease model in vitro Induced pluripotent stem cells (iPSCs) are generated from Alpers' patient carrying the compound heterozygous mutations of A467T (c.1399G>A) and P589L (c.1766C>T), followed by differentiation into cortical organoids and neural stem cells (NSCs). Alpers's iPSCs exhibit mild mitochondrial alterations, including an elevated L-lactate level and a depletion of CI. Alpers' NSCs manifest profound mtDNA depletion and mitochondrial dysfunction. Alpers' cortical organoids demonstrate cortical neuronal loss and astrocyte accumulation. The role of NR in Alpers' cortical organoids Long-term treatment with NR partially ameliorates the neurodegenerative alterations observed in Alpers' cortical organoids. Specifically, supplementation of NR effectively counteracts neuronal loss, glial enrichment, and mitochondrial damage observed in cortical organoids of patients with Alpers' disease. Reversal of the dysregulated pathways in Alpers' patient organoids post NR treatment NR treatment offsets the downregulation of mitochondrial and synaptogenesis-related pathways, as well as upregulation of pathways associated with astrocyte/glial cells and neuroinflammation are obviously activated in Alpers' cortical organoids. Conclusion Replenishment of NR to increase NAD level can rescue mitochondrial defects and neuronal loss in iPSC-derived cortical organoid of Alpers’ disease, with relatively high safety and bioavailability, showing great promise as a therapeutic candidate for this intractable disorder. Reference Hong Y, Zhang Z, Yangzom T, et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease. Int J Biol Sci. 2024;20(4):1194-1217. Published 2024 Jan 25. doi:10.7150/ijbs.91624 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 173 BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The opinions expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
1. Introduction On July 2023, the World Health Organization (WHO) has classified the soda sweetener aspartame as a possible carcinogen, but said that aspartame is safe to consume within a daily limit of 40 milligrams per kilogram of a person’s body weight according to the latest assessment results regarding the impacts of the non-sugar sweetener aspartame upon the health. How about another sweetener stevioside? Is stevioside a sugar reducer or a health killer? 2. Current situation on stevioside Stevioside (also termed stevia glycoside) has been regarded as “the third largest source of natural sugar across the world” by virtue of its low calorie, high sweetness, good stability and low price, which is widely used in medicine, daily chemicals, beverage, food, brewing and other industries. 3. Regulatory application and control of stevioside The aforementioned report of WHO on the possible carcinogenesis of soda sweetener aspartame is based on high intake. An adult weighing 70 kilograms or 154 pounds would have to drink more than 9 to 14 cans of aspartame-containing soda daily to exceed the limit and potentially face health risks. There is no need to be worry about the risk of carcinogenesis in the case of healthy intake. The same situation is applicable to another sweetener stevioside. Stevioside is approved to be sweetener in food in countries like Mainland China, Japan, Korea, Australia, New Zealand, the USA and European Union. In China, there are detail specifications on the food additive stevioside (GB 2760-2014). 4. The therapeutic properties of stevioside 4.1 Antitumor effect Stevioside can be applied as a valuable chemotherapy candidate to be further investigated for cancer therapy. The activity of the well-known tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), is successfully inhibited with stevioside in a murine skin-cancer model. In addition, stevioside can reduce mammary adenoma incidence in F344 rats. 4.2 Anti-hypertensive activity The hypotensive effect observed in rats after chronic oral administration (30 days) of 2.67 g stevia leaves/day has been confirmed in spontaneously hypertensive rats. In that murine model, stevioside (100 mg/kg; i.v.) is able to reduce blood pressure with no change in serum epinephrine, norepinephrine, or dopamine levels. 4.3 Anti-diabetics In diabetic rats, stevioside (0.2 g/kg; i.v. administration) decreases glucose blood levels, yet increases insulin responses and reactions to an intravenous glucose tolerance test (IVGT). Also, stevioside enhances insulin levels above basal during the IVGT, without altering blood glucose response, in normal rats, hinting its potential as a drug candidate for type 2 diabetes. 4.4 Inhibition of pathogenic bacteria Stevioside has demonstrated antibacterial action on various foodborne pathogenic bacteria, including Escherichia coli, a wellknown etiologic agent of severe diarrhea. Regarding antiviral properties, stevioside seems to impede binding of rotavirus to host cells. Rotavirus is commonly associated with pediatric gastroenteritis. 4.5 Anti-inflammatory property In lipopolysaccharide (LPS)-stimulated THP1 cells, stevioside (1mM) inhibits NF-κB. Moreover, stevioside prevents in vitro upregulation of genes involved in liver inflammation. In addition, silico assays demonstrate its antagonistic action in two proinflammatory receptors: tumor necrosis factor receptor (TNFR)-1 and Toll-like receptor (TLR)-4-MD2. 4.6 Antioxidant capability The antioxidant effects of stevioside and rebaudioside A have been confirmed in a fish model, both of which effectively control lipoperoxidation and protein carbonylation. Furthermore, stevioside prevents oxidative DNA damage in the livers and kidneys of a type 2 diabetes murine model. 5 Conclusion As long as the intake is properly controlled, stevioside can be very useful. Stevioside holds a great promise in the clinical treatment and daily health care. Reference Orellana-Paucar A. M. (2023). Steviosides from Stevia rebaudiana: An Updated Overview of Their Sweetening Activity, Pharmacological Properties, and Safety Aspects. Molecules (Basel, Switzerland), 28(3), 1258. https://doi.org/10.3390/molecules28031258 BONTAC Stevioside Reb-D product features and advantages BONTAC possesses the international application and authorized patents on Stevioside Reb-D (US11312948B2 & ZL2018800019752), where the product quality (purity and stability) can be better ensured. Disclaimer BONTAC shall hold no responsibility for any claims arising directly or indirectly from your reliance on the information and material on this website.
Introduction On March 28, 2024, Digital Health and Precise Nutrition Forum & Annual Conference of Health Industry in 2023 is held in Shenzhen, China. By virtue of the technical innovation in synthetic biology, far-reaching industry impact and positive commitment to social responsibility, BONTAC has been awarded 4 more honors in the heath industry, namely the "The Benchmarking Enterprise of Shenzhen Health Industry in 2023", "The Most Valuable Investment Enterprise of Shenzhen Health Industry in 2023", "Special Contribution Award for Shenzhen Health Industry in 2023" and "The Excellent Case in Shenzhen Health Industry Development Report (2022)". About Digital Health and Precise Nutrition Forum & Annual Conference of Health Industry in 2023 This conference is organized by Shenzhen Health Industry Alliance, Shenzhen Association for the Development & Promotion of Health Industry and Shenzhen Health Care Association, aiming to award and recognize the paragons in the health industry who make great contributions with their practical actions. They represent the top level and mainstream of Shenzhen in health industry. Evaluation criteria for two of the awards As for “The Most Valuable Investment Enterprise of Shenzhen Health Industry in 2023", one should be equipped with: * Market share, brand impact and technical innovation ability * Explicit goal, customer demand and operation means * Leading technology, products or services * Management team with abundant experience and professional ability For the Benchmarking Enterprise of Shenzhen Health Industry in 2023, the selected enterprises should have: * Certain industry impacts * Achievement in scientific innovation, intellectual property, etc. * Active participation in the drafting of international/national/industry standard * An efficient and professional team * Positive commitment to the social responsibility Professor Zhang’s speech in round-table dialogue Professor Zhang, the chief scientist and founder in BONTAC, has been invited to participate in the round-table dialogue themed by “Digitization Empowers Nutrition and Health”. She shares profound and unique insights upon the research and practice of coenzyme raw materials in the field of precise nutrition. “BONTAC realizes the efficient synthesis and precise application of coenzyme raw materials in the fields such as food, agriculture and animal nutrition through deep integration of big data with AI technology”, Professor Zhang said. “We not only focus on the extensive use of coenzyme raw materials, but also emphasize their safety and function, with the purpose of satisfying everyone's demand on precise nutrition as well as promoting the continuous innovation and development of the health industry. Novel trend towards health industry Under the guidance of “Health China” strategy, there is an increasing trend towards to the deep integration of digital industry with health industry in current society. The reform of digital technology opens up unprecedented opportunities for the health industry, driving the intelligence, precision and personalization of health. In Shenzhen, a new blueprint for the high-quality development of “20+8” industry clusters (top 20 strategic emerging industrial clusters and 8 industries of the future) has been plotted in 2023. With the continuous optimization of industry structure, the health industry in Shenzhen has been developed rapidly, which infuses new energy for the economy and provides solid support for the citizen’s health and well-being. BONTAC as a driver of health and well-being BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, who adheres to adopt the innovation-driven scientific strategy, with more than 170 invention patents, making great contributions to the health industry. Strikingly, a independent platform for directed evolution has been established in BONTAC, where premium enzyme species can be screened by AI to provide strong support for the production of high-quality coenzyme raw materials, driving the integration of digital industry with health industry. In 2024, BONTAC will continue to stick to our mission of “Green Bio-Tech, Healthier and Better Life!” and actively respond to the appeal in “Outline of the Program for Health China 2030”, promoting the deep integration of synthetic biology with health industry and constructing a better health service system.